Published in AIDS on March 13, 2011
HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science (2014) 3.80
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Improving Bayesian population dynamics inference: a coalescent-based model for multiple loci. Mol Biol Evol (2012) 2.02
Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog (2013) 1.85
Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters. J Infect Dis (2013) 1.74
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68
High HIV burden among people who inject drugs in 15 Indian cities. AIDS (2015) 1.60
Cell Surface Proteomic Map of HIV Infection Reveals Antagonism of Amino Acid Metabolism by Vpu and Nef. Cell Host Microbe (2015) 1.58
Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2013) 1.51
Rapid detection of HIV-1 proviral DNA for early infant diagnosis using recombinase polymerase amplification. MBio (2013) 1.50
Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries. AIDS Res Hum Retroviruses (2012) 1.50
Community viral load, antiretroviral therapy coverage, and HIV incidence in India: a cross-sectional, comparative study. Lancet HIV (2016) 1.47
Recombination form and epidemiology of HIV-1 unique recombinant strains identified in Yunnan, China. PLoS One (2012) 1.43
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One (2013) 1.40
Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One (2012) 1.31
HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology (2013) 1.30
Using HIV networks to inform real time prevention interventions. PLoS One (2014) 1.29
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C. PLoS One (2012) 1.25
Genome sequence of a novel HIV-1 circulating recombinant form 54_01B from Malaysia. J Virol (2012) 1.25
Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors. J Virol (2011) 1.25
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One (2013) 1.24
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Efficient on-chip isolation of HIV subtypes. Lab Chip (2012) 1.17
HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data. Infect Agent Cancer (2011) 1.16
Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J Biol Chem (2012) 1.16
COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res (2014) 1.15
Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol (2013) 1.11
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther (2014) 1.08
Deep sequencing: becoming a critical tool in clinical virology. J Clin Virol (2014) 1.07
Impact of HIV subtype on performance of the limiting antigen-avidity enzyme immunoassay, the bio-rad avidity assay, and the BED capture immunoassay in Rakai, Uganda. AIDS Res Hum Retroviruses (2013) 1.05
Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest? J Acquir Immune Defic Syndr (2014) 1.03
Mechanisms and factors that influence high frequency retroviral recombination. Viruses (2011) 1.02
Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology (2013) 1.01
A newly emerging HIV-1 recombinant lineage (CRF58_01B) disseminating among people who inject drugs in Malaysia. PLoS One (2014) 1.01
A species-specific amino acid difference in the macaque CD4 receptor restricts replication by global circulating HIV-1 variants representing viruses from recent infection. J Virol (2012) 1.00
Are subtype differences important in HIV drug resistance? Curr Opin Virol (2012) 0.99
High HIV prevalence and incidence among MSM across 12 cities in India. AIDS (2015) 0.99
Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. J Immunol Methods (2014) 0.97
Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol (2014) 0.96
Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades. PLoS One (2014) 0.96
Large-scale analysis of the prevalence and geographic distribution of HIV-1 non-B variants in the United States. J Clin Microbiol (2013) 0.95
Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2014) 0.93
Characterization of HIV-1 gag and nef in Cameroon: further evidence of extreme diversity at the origin of the HIV-1 group M epidemic. Virol J (2013) 0.93
Arc of a vicious circle: pathways activated by Mycobacterium tuberculosis that target the HIV-1 long terminal repeat. Am J Respir Cell Mol Biol (2011) 0.93
An integrated map of HIV genome-wide variation from a population perspective. Retrovirology (2015) 0.93
The influence of delivery vectors on HIV vaccine efficacy. Front Microbiol (2014) 0.92
Origin and diversity of human retroviruses. AIDS Rev (2014) 0.92
Overview of the current state of the epidemic. Curr HIV/AIDS Rep (2013) 0.91
HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrob Agents Chemother (2012) 0.91
HIV-1 subtype C is not associated with higher risk of heterosexual HIV-1 transmission: a multinational study among HIV-1 serodiscordant couples. AIDS (2014) 0.91
Phylodynamics of HIV-1 subtype C epidemic in east Africa. PLoS One (2012) 0.90
Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses. J Clin Microbiol (2011) 0.90
Effects of political conflict-induced treatment interruptions on HIV drug resistance. AIDS Rev (2013) 0.90
The origin and evolutionary history of HIV-1 subtype C in Senegal. PLoS One (2012) 0.89
Regulation of Mycobacterium tuberculosis-dependent HIV-1 transcription reveals a new role for NFAT5 in the toll-like receptor pathway. PLoS Pathog (2012) 0.89
Evolution of foamy viruses: the most ancient of all retroviruses. Viruses (2013) 0.89
Searching for virus phylotypes. Bioinformatics (2013) 0.89
HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, Brazil. PLoS One (2014) 0.89
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS (2014) 0.89
A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. PLoS Comput Biol (2013) 0.88
Formation of a unique cluster of G-quadruplex structures in the HIV-1 Nef coding region: implications for antiviral activity. PLoS One (2013) 0.87
HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. AIDS Res Hum Retroviruses (2015) 0.87
Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J Virol (2014) 0.87
Reliable genotypic tropism tests for the major HIV-1 subtypes. Sci Rep (2015) 0.87
Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. J Infect Dis (2015) 0.87
Extensive Genetic Diversity of HIV-1 in Incident and Prevalent Infections among Malaysian Blood Donors: Multiple Introductions of HIV-1 Genotypes from Highly Prevalent Countries. PLoS One (2016) 0.87
Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B. J Acquir Immune Defic Syndr (2013) 0.86
Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy. AIDS Res Hum Retroviruses (2012) 0.86
Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines. AIDS Res Hum Retroviruses (2013) 0.86
Molecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, Rwanda. PLoS One (2012) 0.85
Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasma. PLoS One (2014) 0.85
Update on current management of chronic kidney disease in patients with HIV infection. Int J Nephrol Renovasc Dis (2016) 0.85
HIV-1 diversity, transmission dynamics and primary drug resistance in Angola. PLoS One (2014) 0.85
Spatiotemporal dynamics of the HIV-1 subtype G epidemic in West and Central Africa. PLoS One (2014) 0.85
Genetic diversity and naturally polymorphisms in HIV type 1 integrase isolates from Maputo, Mozambique: implications for integrase inhibitors. AIDS Res Hum Retroviruses (2012) 0.85
The International Dimension of the U.S. HIV Transmission Network and Onward Transmission of HIV Recently Imported into the United States. AIDS Res Hum Retroviruses (2016) 0.85
HIV-1 subtypes B and C unique recombinant forms (URFs) and transmitted drug resistance identified in the Western Cape Province, South Africa. PLoS One (2014) 0.85
Molecular characterization of unique intersubtype HIV type 1 A1/C recombinant strain circulating in Pune, India. AIDS Res Hum Retroviruses (2013) 0.85
Future of phylogeny in HIV prevention. J Acquir Immune Defic Syndr (2013) 0.85
Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. Viruses (2014) 0.85
Multiple independent introductions of HIV-1 CRF01_AE identified in China: what are the implications for prevention? PLoS One (2013) 0.85
Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay. J Acquir Immune Defic Syndr (2014) 0.84
An HIV epidemic model based on viral load dynamics: value in assessing empirical trends in HIV virulence and community viral load. PLoS Comput Biol (2014) 0.84
Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials. PLoS One (2011) 0.84
Identification of new splice sites used for generation of rev transcripts in human immunodeficiency virus type 1 subtype C primary isolates. PLoS One (2012) 0.84
Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study. J Virol (2015) 0.84
Toward a robust monitoring of HIV subtypes distribution worldwide. AIDS (2011) 0.84
Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research. J Virol (2015) 0.84
Determination of HIV Status in African Adults With Discordant HIV Rapid Tests. J Acquir Immune Defic Syndr (2015) 0.84
Determination of the high prevalence of Dual/Mixed- or X4-tropism among HIV type 1 CRF01_AE in Hong Kong by genotyping and phenotyping methods. AIDS Res Hum Retroviruses (2013) 0.83
Phylogenetic and geospatial evaluation of HIV-1 subtype diversity at the largest HIV center in Rhode Island. Infect Genet Evol (2014) 0.83
Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro. PLoS One (2012) 0.83
Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice. Curr HIV Res (2015) 0.83
Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res (2014) 0.83
Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures. PLoS One (2014) 0.83
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
HIV-1 nomenclature proposal. Science (2000) 6.61
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006) 5.31
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature (2008) 5.05
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull (2001) 4.41
Challenges in the development of an HIV-1 vaccine. Nature (2008) 4.32
A new human immunodeficiency virus derived from gorillas. Nat Med (2009) 3.47
Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol (2007) 3.05
Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis (2006) 3.03
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
T cell cross-reactivity and conformational changes during TCR engagement. J Exp Med (2004) 1.99
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis (2009) 1.96
Spatial phylodynamics of HIV-1 epidemic emergence in east Africa. AIDS (2009) 1.91
HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda. AIDS (2009) 1.72
Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc (2009) 1.65
No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res Hum Retroviruses (2005) 1.47
Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS (2004) 1.41
Short communication: identification of a novel HIV type 1 subtype H/J recombinant in Canada with discordant HIV viral load (RNA) values in three different commercial assays. AIDS Res Hum Retroviruses (2007) 1.22
HIV vaccines: mosaic approach to virus diversity. Nat Med (2010) 1.05
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Integrating HIV prevention and treatment: from slogans to impact. PLoS Med (2005) 6.73
Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis (2002) 6.73
The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med (2006) 6.53
Methods and procedures for estimating HIV/AIDS and its impact: the UNAIDS/WHO estimates for the end of 2001. AIDS (2003) 5.88
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006) 5.31
Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet (2002) 5.21
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet (2004) 4.13
Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis (2003) 4.10
Estimates of HIV-1 prevalence from national population-based surveys as a new gold standard. Lancet (2003) 3.85
Child mortality and HIV infection in Africa: a review. AIDS (2004) 3.02
AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis (2006) 2.82
Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis (2005) 2.80
The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science (2006) 2.76
HIV infection does not disproportionately affect the poorer in sub-Saharan Africa. AIDS (2007) 2.67
Improving facility-based care for sick children in Uganda: training is not enough. Health Policy Plan (2005) 2.61
Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol (2011) 2.41
Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ (2006) 2.20
Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic? Lancet (2004) 2.20
GB virus type C coinfection in HIV-infected African mothers and their infants, KwaZulu Natal, South Africa. Clin Infect Dis (2004) 2.08
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03
Back to basics in HIV prevention: focus on exposure. BMJ (2003) 1.99
Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg (2004) 1.98
Improving quality and efficiency of facility-based child health care through Integrated Management of Childhood Illness in Tanzania. Health Policy Plan (2005) 1.77
The epidemiology of HIV infection among young people aged 15-24 years in southern Africa. AIDS (2008) 1.77
Improved estimates of India's HIV burden in 2006. Indian J Med Res (2009) 1.70
Prevalence of HIV among truck drivers visiting sex workers in KwaZulu-Natal, South Africa. Sex Transm Dis (2002) 1.66
Estimates of HIV incidence from household-based prevalence surveys. AIDS (2010) 1.59
Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods. PLoS One (2011) 1.56
New strategies for HIV surveillance in resource-constrained settings: an overview. AIDS (2005) 1.56
Effect of Integrated Management of Childhood Illness (IMCI) on health worker performance in Northeast-Brazil. Cad Saude Publica (2004) 1.52
The impact of incident and prevalent herpes simplex virus-2 infection on the incidence of HIV-1 infection among commercial sex workers in South Africa. J Acquir Immune Defic Syndr (2005) 1.51
Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One (2012) 1.48
Changing patterns of knowledge, reported behaviour and sexually transmitted infections in a South African gold mining community. AIDS (2003) 1.42
Knowing your HIV/AIDS epidemic and tailoring an effective response: how did India do it? Sex Transm Infect (2012) 1.40
Diabetes and other disorders of glycemia in a rural South African community: prevalence and associated risk factors. Diabetes Care (2008) 1.40
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
Advances and future directions in HIV surveillance in low- and middle-income countries. Curr Opin HIV AIDS (2009) 1.25
The distribution of new HIV infections by mode of exposure in Morocco. Sex Transm Infect (2013) 1.24
Estimation of antiretroviral therapy coverage: methodology and trends. Curr Opin HIV AIDS (2010) 1.21
HIV prevalence and risk behavior among clients of female sex workers in Abidjan, Côte d'Ivoire. AIDS (2003) 1.16
Understanding the modes of transmission model of new HIV infection and its use in prevention planning. Bull World Health Organ (2012) 1.14
Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine (2011) 1.13
Estimation of "needs" and "probable uptake" for HIV/AIDS preventive vaccines based on possible policies and likely acceptance (a WHO/UNAIDS/IAVI study). Vaccine (2003) 1.12
New insights into the origin of the HIV type 1 subtype A epidemic in former Soviet Union's countries derived from sequence analyses of preepidemically transmitted viruses. AIDS Res Hum Retroviruses (2007) 1.10
Past, present and future of HIV vaccine trials in developing countries. Vaccine (2002) 1.07
Global epidemiology of HIV-AIDS. Infect Dis Clin North Am (2007) 1.06
Testing the accuracy of demographic estimates in countries with generalized epidemics. AIDS (2004) 1.02
Measuring the impact of the global response to the AIDS epidemic: challenges and future directions. J Acquir Immune Defic Syndr (2009) 0.99
International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One (2012) 0.99
Status of the HIV/AIDS epidemic and methods to monitor it in the Latin America and Caribbean region. AIDS (2002) 0.98
Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res (2011) 0.98
Development and future directions for the Joint United Nations Programme on HIV/AIDS estimates. AIDS (2014) 0.96
The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy. AIDS (2014) 0.95
Molecular epidemiology of HIV-1 in St Petersburg, Russia: predominance of subtype A, former Soviet Union variant, and identification of intrasubtype subclusters. J Acquir Immune Defic Syndr (2009) 0.94
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med (2010) 0.89
High HIV-1 genetic diversity in Cuba. AIDS (2002) 0.86
AIDS in Africa. Lancet (2002) 0.85
The use of epidemiological data to inform the PEPFAR response. J Acquir Immune Defic Syndr (2012) 0.85
Epidemiological Trends for HIV in Southern Africa: Implications for Reaching the Elimination Targets. Curr HIV/AIDS Rep (2015) 0.84
Using HIV surveillance data: recent experiences and avenues for the future. AIDS (2005) 0.83
The analysis of near full-length genome sequences of HIV type 1 subtype A viruses from Russia supports the monophyly of major intrasubtype clusters. AIDS Res Hum Retroviruses (2012) 0.82
Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan). Southeast Asian J Trop Med Public Health (2011) 0.82
Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J Trop Med Public Health (2008) 0.82
Short communication: Molecular epidemiology of HIV type 1 in the Republic of Dagestan, Russian Federation: virtually uniform circulation of subtype A, former Soviet Union variant, with predominance of the V77I(PR) subvariant. AIDS Res Hum Retroviruses (2010) 0.82
European Union and EDCTP strategy in the global context: recommendations for preventive HIV/AIDS vaccines research. Vaccine (2005) 0.82
Ensuring quality: a key consideration in scaling-up HIV-related point-of-care testing programs. AIDS (2016) 0.82
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. Curr Opin HIV AIDS (2010) 0.81
HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. Hum Immunol (2004) 0.81
Near full-length genome characterization of a newly identified HIV type 1 subtype F variant circulating in St. Petersburg, Russia. AIDS Res Hum Retroviruses (2009) 0.80
Developments in the field of HIV estimates: methods, parameters and trends. Sex Transm Infect (2012) 0.79
Integrated Management of Childhood Illness: efficiency of primary health in Northeast Brazil. Rev Saude Publica (2008) 0.78
Assessment of the validity of and adherence to sexually transmitted infection algorithms at a female sex worker clinic in Abidjan, Côte d'Ivoire. Sex Transm Dis (2003) 0.78
HIV prevalence measurement in household surveys: is awareness of HIV status complicating the gold standard? AIDS (2013) 0.77
Level of viral suppression and the cascade of HIV care in a South African semi-urban setting in 2012. AIDS (2016) 0.76
Representative sampling and analysis in HIV molecular epidemiology studies. AIDS (2008) 0.76
Correction: What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach. PLoS One (2016) 0.75
Putting the burden of HIV in context. AIDS (2013) 0.75
Editorial: methodological developments in the Joint United Nations Programme on HIV/AIDS estimates. AIDS (2017) 0.75